SlideShare a Scribd company logo
UNDERSTANDING THE NEW
OPIOID RULES
BY:
RENALDO P. DeFRANK, JR.
LEVASSEUR & DEFRANK, P.C.
September 23, 2015
WHAT ARE OPIOIDS?
• Opioids are medications
that are prescribed to
relieve acute/chronic
pain
• Most opioids come in pill
or tablet form and can be
taken by mouth, but they
can also be prescribed in
patch form
• Common opioids being
prescribed are
hydrocodone (e.g.
Vicodin), oxycodone (e.g.
Oxycontin, Percocet) and
morphine (e.g. Kadian)
INTRODUCTION OF OPIOIDS TO THE
INJURED WORKER
• Treatment is provided to an injured worker
after an injury
• Physician determines that the degree of pain
merits the use of opioids
• The injured worker begins taking the
prescribed medication
• The path of opioid use begins!
CHRONIC PAIN
• Chronic pain exists beyond an
expected time for healing. It is
a persistent pain state not
associated with malignancy or
acute pain caused by trauma,
surgery infection or other
factors. However, these and
other pain sources, such as
sprains or twists, may
symptomatically persist to
become chronic benign pain.
The intensity will vary from
mild to severe disabling pain
that may significantly reduce
quality of life
OPIOID CONCERNS
• Dependence
• Addiction
• Abuse
– Over medicating
– Overdosing
– Selling the opioids to make $$$
• High medical costs
• Legal exposure
• Medicare!!!
THE OPIOID MOVEMENT
• In October 2014, the FDA reclassified combination drugs with
hydrocodone as Schedule II drugs (HIGH POTENTIAL FOR ABUSE!!!)
• Methadone and Oxycodone are also Schedule II drugs
• This requires patients to see their doctors to obtain new
prescriptions, as opposed to obtaining refills without an office visit
• The reclassification limits somewhat the ease of access to opioids
AMENDMENTS TO THE WORKERS’
COMPENSATION RULES
• The Michigan Workers’ Compensation Agency (WCA) amended the
Workers’ Compensation Health Care Services rules and fee
schedule, effective December 26, 2014
• The amendments were put in place to address the problem of long-
term use of opioids by injured workers and help reduce medical
costs for the State’s job providers
• Limit potential addiction problems for injured workers, to keep
them healthy and get them back to work
• Rule 1008. (1) For purposes of these rules, chronic pain is
pain unrelated to cancer or is incident to surgery and
that persists beyond the period of expected healing after
an acute injury episode. It is pain that persists beyond 90
days following the onset of the pain. The payer shall
reimburse for opioids used in the treatment of chronic
pain resulting from work-related conditions.
• (2) This rule is applicable to opioid treatment of chronic
pain for the following: (a) Injury dates on or after June
26, 2015. (b) Beginning December 26, 2015, all other
injury dates.
R 418.101008 Reimbursement for opioid
treatment for chronic, non-cancer pain
R 418.101008a Required documentation for
reimbursement of treatment for chronic, non-cancer
pain with opioids.
• Rule 1008a. (1) In order to receive reimbursement for opioid
treatment beyond 90 days, the physician seeking reimbursement
shall submit a written report to the payer not later than 90 days
after the initial opioid prescription fill for chronic pain and every 90
days thereafter. The written report shall include all of the following:
• (a) A review and analysis of the relevant prior medical history,
including any consultations that have been obtained, and a review
of data received from an automated prescription drug monitoring
program in the treating jurisdiction, such as the Michigan
Automated Prescription System (MAPS), for identification of past
history of narcotic use and any concurrent prescriptions.
• (b) A summary of conservative care rendered to the worker that
focused on increased function and return to work.
• (c) A statement on why prior or alternative conservative measures
were ineffective or contraindicated.
• (d) A statement that the attending physician has considered the
results obtained from appropriate industry accepted screening tools
to detect factors that may significantly increase the risk of abuse or
adverse outcomes including a history of alcohol or other substance
abuse.
• (e) A treatment plan which includes all of the following: (i) Overall
treatment goals and functional progress. (ii) Periodic urine drug
screens. (iii) A conscientious effort to reduce pain through the use
of non-opioid medications, alternative non-pharmaceutical
strategies, or both. (iv) Consideration of weaning the injured worker
from opioid use.
• (f) An opioid treatment agreement that has been signed by the
worker and the attending physician. This agreement shall be
reviewed, updated, and renewed every 6 months. The opioid
treatment agreement shall outline the risks and benefits of opioid
use, the conditions under which opioids will be prescribed, and the
responsibilities of the prescribing physician and the worker.
• (2) The provider may bill the additional services required for
compliance with these rules utilizing CPT procedure code 99215 for
the initial 90 day report and all subsequent follow-up reports at 90-
day intervals.
• (3) Providers may bill $25.00 utilizing code MPS01 for accessing
MAPS or other automated prescription drug monitoring program in
the treating jurisdiction.
R 418.101008b Denial of reimbursement for
prescribing and dispensing opioid medications used to
treat chronic, non-cancer pain.
• Rule 1008b. Reimbursement for prescribing and dispensing opioid
medications may be denied, pursuant to the act. Denial of
reimbursement may occur if the physician reporting and treatment
plan requirements as stated in R 418.101008a are not met. Denial
of reimbursement shall occur only after a reasonable period of
time is provided for the weaning of the injured worker from the
opioid medications, and alternative means of pain management
have been offered.
WHAT DOES ALL OF THIS MEAN?
• Limits the ease to which
opioids are prescribed
• Extra hoops for physicians
to jump through in order
to get paid
• Detailed reports to
support the need for
opioid treatment
• Potential to curb the
prescription of opioids in
the first place
MAPS!
IMPACT ON WORK COMP CLAIMS
• Opioids are the most common
treatment for chronic pain
– A 2013 study found that 30%
of physician visits for back
and/or neck pain resulted in a
prescription for opioids
– As many as 90% of pain
management patients in the
U.S. receive opioids for
chronic pain
– 50% of patients who take
opioids daily for 90 days are
still taking them daily 5 years
later
LEADING PRESCRIBERS
WHAT DO THESE STATS MEAN?
• The stats show that family physicians, as opposed to pain
management specialists, are prescribing most of the opioids being
used today
• Once an injured worker goes down the opioid route, the odds of
long-term opioid use is significant
• Potential problems are on the horizon
WHY SHOULD YOU CARE ABOUT
OPIOID USE?
• Cost of opioids is high
– Future medical treatment costs will be significant
– Need for periodic drug testing
– Potential need for a drug weaning program
– Increases the exposure of a given workers’ compensation claim
– Could lead to a large MSA amount and be an impediment to
settlement
HOW TO AVOID OPIOID PROBLEMS
• Be sure to direct medical care for the first 28 days after an injury
occurs
– Could prevent the opioid cycle from starting
• If/when opioids are being discussed as part of a treatment plan,
consider a second opinion (e.g. IME)
• Consider the use of a Nurse Case Manager (NCM) to oversee the
treatment plan, once opioids are prescribed
– Discuss alternatives to opioid treatment
– Monitor the reports from the physicians in support of the
continued use of opioids
– Once opioids are being used, determine the appropriate plan to
wean the injured worker off of the opioids
• Contact an attorney to discuss the claim
QUESTIONS?
Renaldo P. DeFrank, Jr.
LeVasseur & DeFrank, P.C.
24725 W. 12 Mile Rd., Ste 230
Southfield, MI 48034
Office: 248-356-8600
Cell: 248-207-6365
www.levasseurlaw.com
rdefrank@levasseurlaw.com

More Related Content

What's hot

Presentation: Spotlight on complementary medicines MMDR reforms
Presentation: Spotlight on complementary medicines MMDR reformsPresentation: Spotlight on complementary medicines MMDR reforms
Presentation: Spotlight on complementary medicines MMDR reforms
TGA Australia
 
Pharmacovigilance a general overview most updated
Pharmacovigilance  a general overview  most updatedPharmacovigilance  a general overview  most updated
Pharmacovigilance a general overview most updated
peter donik
 
International society of pharmacovigilance (IsOP) training course: Early acce...
International society of pharmacovigilance (IsOP) training course: Early acce...International society of pharmacovigilance (IsOP) training course: Early acce...
International society of pharmacovigilance (IsOP) training course: Early acce...
TGA Australia
 
Pharmacovigilance & pv pi
Pharmacovigilance & pv piPharmacovigilance & pv pi
Pharmacovigilance & pv pi
NikhilNaikwadi3
 
Pharmacovigilance nrsmch
Pharmacovigilance nrsmchPharmacovigilance nrsmch
Pharmacovigilance nrsmch
Anindya Banerjee
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
Valencia Fernandes
 
Presentation: A spotlight on other reforms from the medicines and medical dev...
Presentation: A spotlight on other reforms from the medicines and medical dev...Presentation: A spotlight on other reforms from the medicines and medical dev...
Presentation: A spotlight on other reforms from the medicines and medical dev...
TGA Australia
 
Risk management plans - an overview
Risk management plans - an overviewRisk management plans - an overview
Risk management plans - an overview
TGA Australia
 
ROLE OF PHARMACOVIGILANCE AGAINST ADVERSE DRUG REACTION
ROLE OF PHARMACOVIGILANCE AGAINST ADVERSE DRUG REACTIONROLE OF PHARMACOVIGILANCE AGAINST ADVERSE DRUG REACTION
ROLE OF PHARMACOVIGILANCE AGAINST ADVERSE DRUG REACTION
Anindya Banerjee
 
TGA Presentation: TGA Approval Pathways
TGA Presentation: TGA Approval PathwaysTGA Presentation: TGA Approval Pathways
TGA Presentation: TGA Approval Pathways
TGA Australia
 
Prescription Medicines MMDR Reforms
Prescription Medicines MMDR ReformsPrescription Medicines MMDR Reforms
Prescription Medicines MMDR Reforms
TGA Australia
 
Pharmacovigilance in Australia
Pharmacovigilance in AustraliaPharmacovigilance in Australia
Pharmacovigilance in Australia
Saeeda Hasan
 
History n progress of pv
History n progress of pvHistory n progress of pv
History n progress of pv
Ramavath Aruna
 
Pharmacovigilance and complementary medicines - Regulatory requirements
Pharmacovigilance and complementary medicines - Regulatory requirementsPharmacovigilance and complementary medicines - Regulatory requirements
Pharmacovigilance and complementary medicines - Regulatory requirements
TGA Australia
 
Current Pharmacovigilance Practice And Improving Methods
Current Pharmacovigilance Practice And Improving MethodsCurrent Pharmacovigilance Practice And Improving Methods
Current Pharmacovigilance Practice And Improving Methods
avinashkhairnar
 
Presentation: Prescription Medicines Reforms
Presentation: Prescription Medicines ReformsPresentation: Prescription Medicines Reforms
Presentation: Prescription Medicines Reforms
TGA Australia
 
TGA presentation: MMDR Consultation - Strengthening monitoring of medicines i...
TGA presentation: MMDR Consultation - Strengthening monitoring of medicines i...TGA presentation: MMDR Consultation - Strengthening monitoring of medicines i...
TGA presentation: MMDR Consultation - Strengthening monitoring of medicines i...
TGA Australia
 
Signifcance of pharmacovigilance & risk management plan
Signifcance of pharmacovigilance & risk management planSignifcance of pharmacovigilance & risk management plan
Signifcance of pharmacovigilance & risk management plan
Ansuman Parida
 
Focussed pharmacovigilance
Focussed pharmacovigilanceFocussed pharmacovigilance
Focussed pharmacovigilance
Dr. Sachin Kumar
 
TGA Presentation: What’s happening in regulation?
TGA Presentation: What’s happening in regulation?TGA Presentation: What’s happening in regulation?
TGA Presentation: What’s happening in regulation?
TGA Australia
 

What's hot (20)

Presentation: Spotlight on complementary medicines MMDR reforms
Presentation: Spotlight on complementary medicines MMDR reformsPresentation: Spotlight on complementary medicines MMDR reforms
Presentation: Spotlight on complementary medicines MMDR reforms
 
Pharmacovigilance a general overview most updated
Pharmacovigilance  a general overview  most updatedPharmacovigilance  a general overview  most updated
Pharmacovigilance a general overview most updated
 
International society of pharmacovigilance (IsOP) training course: Early acce...
International society of pharmacovigilance (IsOP) training course: Early acce...International society of pharmacovigilance (IsOP) training course: Early acce...
International society of pharmacovigilance (IsOP) training course: Early acce...
 
Pharmacovigilance & pv pi
Pharmacovigilance & pv piPharmacovigilance & pv pi
Pharmacovigilance & pv pi
 
Pharmacovigilance nrsmch
Pharmacovigilance nrsmchPharmacovigilance nrsmch
Pharmacovigilance nrsmch
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
 
Presentation: A spotlight on other reforms from the medicines and medical dev...
Presentation: A spotlight on other reforms from the medicines and medical dev...Presentation: A spotlight on other reforms from the medicines and medical dev...
Presentation: A spotlight on other reforms from the medicines and medical dev...
 
Risk management plans - an overview
Risk management plans - an overviewRisk management plans - an overview
Risk management plans - an overview
 
ROLE OF PHARMACOVIGILANCE AGAINST ADVERSE DRUG REACTION
ROLE OF PHARMACOVIGILANCE AGAINST ADVERSE DRUG REACTIONROLE OF PHARMACOVIGILANCE AGAINST ADVERSE DRUG REACTION
ROLE OF PHARMACOVIGILANCE AGAINST ADVERSE DRUG REACTION
 
TGA Presentation: TGA Approval Pathways
TGA Presentation: TGA Approval PathwaysTGA Presentation: TGA Approval Pathways
TGA Presentation: TGA Approval Pathways
 
Prescription Medicines MMDR Reforms
Prescription Medicines MMDR ReformsPrescription Medicines MMDR Reforms
Prescription Medicines MMDR Reforms
 
Pharmacovigilance in Australia
Pharmacovigilance in AustraliaPharmacovigilance in Australia
Pharmacovigilance in Australia
 
History n progress of pv
History n progress of pvHistory n progress of pv
History n progress of pv
 
Pharmacovigilance and complementary medicines - Regulatory requirements
Pharmacovigilance and complementary medicines - Regulatory requirementsPharmacovigilance and complementary medicines - Regulatory requirements
Pharmacovigilance and complementary medicines - Regulatory requirements
 
Current Pharmacovigilance Practice And Improving Methods
Current Pharmacovigilance Practice And Improving MethodsCurrent Pharmacovigilance Practice And Improving Methods
Current Pharmacovigilance Practice And Improving Methods
 
Presentation: Prescription Medicines Reforms
Presentation: Prescription Medicines ReformsPresentation: Prescription Medicines Reforms
Presentation: Prescription Medicines Reforms
 
TGA presentation: MMDR Consultation - Strengthening monitoring of medicines i...
TGA presentation: MMDR Consultation - Strengthening monitoring of medicines i...TGA presentation: MMDR Consultation - Strengthening monitoring of medicines i...
TGA presentation: MMDR Consultation - Strengthening monitoring of medicines i...
 
Signifcance of pharmacovigilance & risk management plan
Signifcance of pharmacovigilance & risk management planSignifcance of pharmacovigilance & risk management plan
Signifcance of pharmacovigilance & risk management plan
 
Focussed pharmacovigilance
Focussed pharmacovigilanceFocussed pharmacovigilance
Focussed pharmacovigilance
 
TGA Presentation: What’s happening in regulation?
TGA Presentation: What’s happening in regulation?TGA Presentation: What’s happening in regulation?
TGA Presentation: What’s happening in regulation?
 

Similar to UNDERSTANDING THE NEW OPIOID RULES

The Opioid Epidemic - N Elkins
The Opioid Epidemic - N ElkinsThe Opioid Epidemic - N Elkins
Opioid Analgesia Use After Ambulatory Surgery: Mismatch Between Quantities Pr...
Opioid Analgesia Use After Ambulatory Surgery: Mismatch Between Quantities Pr...Opioid Analgesia Use After Ambulatory Surgery: Mismatch Between Quantities Pr...
Opioid Analgesia Use After Ambulatory Surgery: Mismatch Between Quantities Pr...
BU School of Medicine
 
Rx15 workshop mon_200_aleshire_dowell_no_notes
Rx15 workshop mon_200_aleshire_dowell_no_notesRx15 workshop mon_200_aleshire_dowell_no_notes
Rx15 workshop mon_200_aleshire_dowell_no_notes
OPUNITE
 
TMB pain management rules
TMB pain management rulesTMB pain management rules
TMB pain management rules
Texas Medical Liability Trust
 
webmm slideshow.ppt
webmm slideshow.pptwebmm slideshow.ppt
webmm slideshow.ppt
ssuser579a28
 
Webinar: Oncology Care Model - Introduction
Webinar: Oncology Care Model - IntroductionWebinar: Oncology Care Model - Introduction
Webinar: Oncology Care Model - Introduction
Centers for Medicare & Medicaid Services (CMS)
 
Antimicrobial stewardship CME 04-03-19
Antimicrobial stewardship CME 04-03-19Antimicrobial stewardship CME 04-03-19
Antimicrobial stewardship CME 04-03-19
Tahseen Siddiqui
 
Controlled Substance Prescribing: What to Do?
Controlled Substance Prescribing: What to Do?Controlled Substance Prescribing: What to Do?
Controlled Substance Prescribing: What to Do?
RIAPA
 
Pharmacoeconomics In India
Pharmacoeconomics In IndiaPharmacoeconomics In India
Pharmacoeconomics In India
Sameer Shete
 
Kathryn Mueller
Kathryn MuellerKathryn Mueller
Kathryn Mueller
OPUNITE
 
MEDICATION ADHERENCE.pptx
MEDICATION ADHERENCE.pptxMEDICATION ADHERENCE.pptx
MEDICATION ADHERENCE.pptx
VarshaBarethiya
 
CDC_Guidelines
CDC_GuidelinesCDC_Guidelines
Audits: Introduction and Procedure
Audits: Introduction and ProcedureAudits: Introduction and Procedure
Audits: Introduction and Procedure
vtesimplified
 
Regulatory Procedures
Regulatory ProceduresRegulatory Procedures
Regulatory Procedures
EURORDIS Rare Diseases Europe
 
Balancing post-market monitoring with pre-market requirements
Balancing post-market monitoring with pre-market requirementsBalancing post-market monitoring with pre-market requirements
Balancing post-market monitoring with pre-market requirements
TGA Australia
 
2011 CPT Changes
2011 CPT Changes2011 CPT Changes
NYU Langone Medical Center’s TJA BPCI Experience: Lessons in How to Maximize ...
NYU Langone Medical Center’s TJA BPCI Experience: Lessons in How to Maximize ...NYU Langone Medical Center’s TJA BPCI Experience: Lessons in How to Maximize ...
NYU Langone Medical Center’s TJA BPCI Experience: Lessons in How to Maximize ...
Wellbe
 
Meaningful Use Stage-1
Meaningful Use Stage-1Meaningful Use Stage-1
Meaningful Use Stage-1
preeti_ipc
 
Rx15 tpp wed_1115_2_fisher_3skinner
Rx15 tpp wed_1115_2_fisher_3skinnerRx15 tpp wed_1115_2_fisher_3skinner
Rx15 tpp wed_1115_2_fisher_3skinner
OPUNITE
 
NURSES_TRAINING_SESSION.pptx,ppt nursing training classes and procedures
NURSES_TRAINING_SESSION.pptx,ppt nursing training classes and proceduresNURSES_TRAINING_SESSION.pptx,ppt nursing training classes and procedures
NURSES_TRAINING_SESSION.pptx,ppt nursing training classes and procedures
MehendiHubb
 

Similar to UNDERSTANDING THE NEW OPIOID RULES (20)

The Opioid Epidemic - N Elkins
The Opioid Epidemic - N ElkinsThe Opioid Epidemic - N Elkins
The Opioid Epidemic - N Elkins
 
Opioid Analgesia Use After Ambulatory Surgery: Mismatch Between Quantities Pr...
Opioid Analgesia Use After Ambulatory Surgery: Mismatch Between Quantities Pr...Opioid Analgesia Use After Ambulatory Surgery: Mismatch Between Quantities Pr...
Opioid Analgesia Use After Ambulatory Surgery: Mismatch Between Quantities Pr...
 
Rx15 workshop mon_200_aleshire_dowell_no_notes
Rx15 workshop mon_200_aleshire_dowell_no_notesRx15 workshop mon_200_aleshire_dowell_no_notes
Rx15 workshop mon_200_aleshire_dowell_no_notes
 
TMB pain management rules
TMB pain management rulesTMB pain management rules
TMB pain management rules
 
webmm slideshow.ppt
webmm slideshow.pptwebmm slideshow.ppt
webmm slideshow.ppt
 
Webinar: Oncology Care Model - Introduction
Webinar: Oncology Care Model - IntroductionWebinar: Oncology Care Model - Introduction
Webinar: Oncology Care Model - Introduction
 
Antimicrobial stewardship CME 04-03-19
Antimicrobial stewardship CME 04-03-19Antimicrobial stewardship CME 04-03-19
Antimicrobial stewardship CME 04-03-19
 
Controlled Substance Prescribing: What to Do?
Controlled Substance Prescribing: What to Do?Controlled Substance Prescribing: What to Do?
Controlled Substance Prescribing: What to Do?
 
Pharmacoeconomics In India
Pharmacoeconomics In IndiaPharmacoeconomics In India
Pharmacoeconomics In India
 
Kathryn Mueller
Kathryn MuellerKathryn Mueller
Kathryn Mueller
 
MEDICATION ADHERENCE.pptx
MEDICATION ADHERENCE.pptxMEDICATION ADHERENCE.pptx
MEDICATION ADHERENCE.pptx
 
CDC_Guidelines
CDC_GuidelinesCDC_Guidelines
CDC_Guidelines
 
Audits: Introduction and Procedure
Audits: Introduction and ProcedureAudits: Introduction and Procedure
Audits: Introduction and Procedure
 
Regulatory Procedures
Regulatory ProceduresRegulatory Procedures
Regulatory Procedures
 
Balancing post-market monitoring with pre-market requirements
Balancing post-market monitoring with pre-market requirementsBalancing post-market monitoring with pre-market requirements
Balancing post-market monitoring with pre-market requirements
 
2011 CPT Changes
2011 CPT Changes2011 CPT Changes
2011 CPT Changes
 
NYU Langone Medical Center’s TJA BPCI Experience: Lessons in How to Maximize ...
NYU Langone Medical Center’s TJA BPCI Experience: Lessons in How to Maximize ...NYU Langone Medical Center’s TJA BPCI Experience: Lessons in How to Maximize ...
NYU Langone Medical Center’s TJA BPCI Experience: Lessons in How to Maximize ...
 
Meaningful Use Stage-1
Meaningful Use Stage-1Meaningful Use Stage-1
Meaningful Use Stage-1
 
Rx15 tpp wed_1115_2_fisher_3skinner
Rx15 tpp wed_1115_2_fisher_3skinnerRx15 tpp wed_1115_2_fisher_3skinner
Rx15 tpp wed_1115_2_fisher_3skinner
 
NURSES_TRAINING_SESSION.pptx,ppt nursing training classes and procedures
NURSES_TRAINING_SESSION.pptx,ppt nursing training classes and proceduresNURSES_TRAINING_SESSION.pptx,ppt nursing training classes and procedures
NURSES_TRAINING_SESSION.pptx,ppt nursing training classes and procedures
 

Recently uploaded

From Promise to Practice. Implementing AI in Legal Environments
From Promise to Practice. Implementing AI in Legal EnvironmentsFrom Promise to Practice. Implementing AI in Legal Environments
From Promise to Practice. Implementing AI in Legal Environments
ssusera97a2f
 
fnaf lore.pptx ...................................
fnaf lore.pptx ...................................fnaf lore.pptx ...................................
fnaf lore.pptx ...................................
20jcoello
 
The Future of Criminal Defense Lawyer in India.pdf
The Future of Criminal Defense Lawyer in India.pdfThe Future of Criminal Defense Lawyer in India.pdf
The Future of Criminal Defense Lawyer in India.pdf
veteranlegal
 
Search Warrants for NH Law Enforcement Officers
Search Warrants for NH Law Enforcement OfficersSearch Warrants for NH Law Enforcement Officers
Search Warrants for NH Law Enforcement Officers
RichardTheberge
 
Defending Weapons Offence Charges: Role of Mississauga Criminal Defence Lawyers
Defending Weapons Offence Charges: Role of Mississauga Criminal Defence LawyersDefending Weapons Offence Charges: Role of Mississauga Criminal Defence Lawyers
Defending Weapons Offence Charges: Role of Mississauga Criminal Defence Lawyers
HarpreetSaini48
 
What are the common challenges faced by women lawyers working in the legal pr...
What are the common challenges faced by women lawyers working in the legal pr...What are the common challenges faced by women lawyers working in the legal pr...
What are the common challenges faced by women lawyers working in the legal pr...
lawyersonia
 
原版制作(PSU毕业证书)宾州州立大学公园分校毕业证学历证书一模一样
原版制作(PSU毕业证书)宾州州立大学公园分校毕业证学历证书一模一样原版制作(PSU毕业证书)宾州州立大学公园分校毕业证学历证书一模一样
原版制作(PSU毕业证书)宾州州立大学公园分校毕业证学历证书一模一样
osenwakm
 
PPT-Money Laundering - lecture 5.pptx ll
PPT-Money Laundering - lecture 5.pptx llPPT-Money Laundering - lecture 5.pptx ll
PPT-Money Laundering - lecture 5.pptx ll
MohammadZubair874462
 
Business Laws Sunita saha
Business Laws Sunita sahaBusiness Laws Sunita saha
Business Laws Sunita saha
sunitasaha5
 
It's the Law: Recent Court and Administrative Decisions of Interest
It's the Law: Recent Court and Administrative Decisions of InterestIt's the Law: Recent Court and Administrative Decisions of Interest
It's the Law: Recent Court and Administrative Decisions of Interest
Parsons Behle & Latimer
 
Lifting the Corporate Veil. Power Point Presentation
Lifting the Corporate Veil. Power Point PresentationLifting the Corporate Veil. Power Point Presentation
Lifting the Corporate Veil. Power Point Presentation
seri bangash
 
Presentation (1).pptx Human rights of LGBTQ people in India, constitutional a...
Presentation (1).pptx Human rights of LGBTQ people in India, constitutional a...Presentation (1).pptx Human rights of LGBTQ people in India, constitutional a...
Presentation (1).pptx Human rights of LGBTQ people in India, constitutional a...
SKshi
 
2015pmkemenhub163.pdf. 2015pmkemenhub163.pdf
2015pmkemenhub163.pdf. 2015pmkemenhub163.pdf2015pmkemenhub163.pdf. 2015pmkemenhub163.pdf
2015pmkemenhub163.pdf. 2015pmkemenhub163.pdf
CIkumparan
 
一比一原版(Lincoln毕业证)新西兰林肯大学毕业证如何办理
一比一原版(Lincoln毕业证)新西兰林肯大学毕业证如何办理一比一原版(Lincoln毕业证)新西兰林肯大学毕业证如何办理
一比一原版(Lincoln毕业证)新西兰林肯大学毕业证如何办理
gjsma0ep
 
Genocide in International Criminal Law.pptx
Genocide in International Criminal Law.pptxGenocide in International Criminal Law.pptx
Genocide in International Criminal Law.pptx
MasoudZamani13
 
Guide on the use of Artificial Intelligence-based tools by lawyers and law fi...
Guide on the use of Artificial Intelligence-based tools by lawyers and law fi...Guide on the use of Artificial Intelligence-based tools by lawyers and law fi...
Guide on the use of Artificial Intelligence-based tools by lawyers and law fi...
Massimo Talia
 
Receivership and liquidation Accounts Prof. Oyedokun.pptx
Receivership and liquidation Accounts Prof. Oyedokun.pptxReceivership and liquidation Accounts Prof. Oyedokun.pptx
Receivership and liquidation Accounts Prof. Oyedokun.pptx
Godwin Emmanuel Oyedokun MBA MSc PhD FCA FCTI FCNA CFE FFAR
 
Sangyun Lee, 'Why Korea's Merger Control Occasionally Fails: A Public Choice ...
Sangyun Lee, 'Why Korea's Merger Control Occasionally Fails: A Public Choice ...Sangyun Lee, 'Why Korea's Merger Control Occasionally Fails: A Public Choice ...
Sangyun Lee, 'Why Korea's Merger Control Occasionally Fails: A Public Choice ...
Sangyun Lee
 
Incometax Compliance_PF_ ESI- June 2024
Incometax  Compliance_PF_ ESI- June 2024Incometax  Compliance_PF_ ESI- June 2024
Incometax Compliance_PF_ ESI- June 2024
EbizfilingIndia
 
在线办理(SU毕业证书)美国雪城大学毕业证成绩单一模一样
在线办理(SU毕业证书)美国雪城大学毕业证成绩单一模一样在线办理(SU毕业证书)美国雪城大学毕业证成绩单一模一样
在线办理(SU毕业证书)美国雪城大学毕业证成绩单一模一样
osenwakm
 

Recently uploaded (20)

From Promise to Practice. Implementing AI in Legal Environments
From Promise to Practice. Implementing AI in Legal EnvironmentsFrom Promise to Practice. Implementing AI in Legal Environments
From Promise to Practice. Implementing AI in Legal Environments
 
fnaf lore.pptx ...................................
fnaf lore.pptx ...................................fnaf lore.pptx ...................................
fnaf lore.pptx ...................................
 
The Future of Criminal Defense Lawyer in India.pdf
The Future of Criminal Defense Lawyer in India.pdfThe Future of Criminal Defense Lawyer in India.pdf
The Future of Criminal Defense Lawyer in India.pdf
 
Search Warrants for NH Law Enforcement Officers
Search Warrants for NH Law Enforcement OfficersSearch Warrants for NH Law Enforcement Officers
Search Warrants for NH Law Enforcement Officers
 
Defending Weapons Offence Charges: Role of Mississauga Criminal Defence Lawyers
Defending Weapons Offence Charges: Role of Mississauga Criminal Defence LawyersDefending Weapons Offence Charges: Role of Mississauga Criminal Defence Lawyers
Defending Weapons Offence Charges: Role of Mississauga Criminal Defence Lawyers
 
What are the common challenges faced by women lawyers working in the legal pr...
What are the common challenges faced by women lawyers working in the legal pr...What are the common challenges faced by women lawyers working in the legal pr...
What are the common challenges faced by women lawyers working in the legal pr...
 
原版制作(PSU毕业证书)宾州州立大学公园分校毕业证学历证书一模一样
原版制作(PSU毕业证书)宾州州立大学公园分校毕业证学历证书一模一样原版制作(PSU毕业证书)宾州州立大学公园分校毕业证学历证书一模一样
原版制作(PSU毕业证书)宾州州立大学公园分校毕业证学历证书一模一样
 
PPT-Money Laundering - lecture 5.pptx ll
PPT-Money Laundering - lecture 5.pptx llPPT-Money Laundering - lecture 5.pptx ll
PPT-Money Laundering - lecture 5.pptx ll
 
Business Laws Sunita saha
Business Laws Sunita sahaBusiness Laws Sunita saha
Business Laws Sunita saha
 
It's the Law: Recent Court and Administrative Decisions of Interest
It's the Law: Recent Court and Administrative Decisions of InterestIt's the Law: Recent Court and Administrative Decisions of Interest
It's the Law: Recent Court and Administrative Decisions of Interest
 
Lifting the Corporate Veil. Power Point Presentation
Lifting the Corporate Veil. Power Point PresentationLifting the Corporate Veil. Power Point Presentation
Lifting the Corporate Veil. Power Point Presentation
 
Presentation (1).pptx Human rights of LGBTQ people in India, constitutional a...
Presentation (1).pptx Human rights of LGBTQ people in India, constitutional a...Presentation (1).pptx Human rights of LGBTQ people in India, constitutional a...
Presentation (1).pptx Human rights of LGBTQ people in India, constitutional a...
 
2015pmkemenhub163.pdf. 2015pmkemenhub163.pdf
2015pmkemenhub163.pdf. 2015pmkemenhub163.pdf2015pmkemenhub163.pdf. 2015pmkemenhub163.pdf
2015pmkemenhub163.pdf. 2015pmkemenhub163.pdf
 
一比一原版(Lincoln毕业证)新西兰林肯大学毕业证如何办理
一比一原版(Lincoln毕业证)新西兰林肯大学毕业证如何办理一比一原版(Lincoln毕业证)新西兰林肯大学毕业证如何办理
一比一原版(Lincoln毕业证)新西兰林肯大学毕业证如何办理
 
Genocide in International Criminal Law.pptx
Genocide in International Criminal Law.pptxGenocide in International Criminal Law.pptx
Genocide in International Criminal Law.pptx
 
Guide on the use of Artificial Intelligence-based tools by lawyers and law fi...
Guide on the use of Artificial Intelligence-based tools by lawyers and law fi...Guide on the use of Artificial Intelligence-based tools by lawyers and law fi...
Guide on the use of Artificial Intelligence-based tools by lawyers and law fi...
 
Receivership and liquidation Accounts Prof. Oyedokun.pptx
Receivership and liquidation Accounts Prof. Oyedokun.pptxReceivership and liquidation Accounts Prof. Oyedokun.pptx
Receivership and liquidation Accounts Prof. Oyedokun.pptx
 
Sangyun Lee, 'Why Korea's Merger Control Occasionally Fails: A Public Choice ...
Sangyun Lee, 'Why Korea's Merger Control Occasionally Fails: A Public Choice ...Sangyun Lee, 'Why Korea's Merger Control Occasionally Fails: A Public Choice ...
Sangyun Lee, 'Why Korea's Merger Control Occasionally Fails: A Public Choice ...
 
Incometax Compliance_PF_ ESI- June 2024
Incometax  Compliance_PF_ ESI- June 2024Incometax  Compliance_PF_ ESI- June 2024
Incometax Compliance_PF_ ESI- June 2024
 
在线办理(SU毕业证书)美国雪城大学毕业证成绩单一模一样
在线办理(SU毕业证书)美国雪城大学毕业证成绩单一模一样在线办理(SU毕业证书)美国雪城大学毕业证成绩单一模一样
在线办理(SU毕业证书)美国雪城大学毕业证成绩单一模一样
 

UNDERSTANDING THE NEW OPIOID RULES

  • 1. UNDERSTANDING THE NEW OPIOID RULES BY: RENALDO P. DeFRANK, JR. LEVASSEUR & DEFRANK, P.C. September 23, 2015
  • 2. WHAT ARE OPIOIDS? • Opioids are medications that are prescribed to relieve acute/chronic pain • Most opioids come in pill or tablet form and can be taken by mouth, but they can also be prescribed in patch form • Common opioids being prescribed are hydrocodone (e.g. Vicodin), oxycodone (e.g. Oxycontin, Percocet) and morphine (e.g. Kadian)
  • 3. INTRODUCTION OF OPIOIDS TO THE INJURED WORKER • Treatment is provided to an injured worker after an injury • Physician determines that the degree of pain merits the use of opioids • The injured worker begins taking the prescribed medication • The path of opioid use begins!
  • 4. CHRONIC PAIN • Chronic pain exists beyond an expected time for healing. It is a persistent pain state not associated with malignancy or acute pain caused by trauma, surgery infection or other factors. However, these and other pain sources, such as sprains or twists, may symptomatically persist to become chronic benign pain. The intensity will vary from mild to severe disabling pain that may significantly reduce quality of life
  • 5. OPIOID CONCERNS • Dependence • Addiction • Abuse – Over medicating – Overdosing – Selling the opioids to make $$$ • High medical costs • Legal exposure • Medicare!!!
  • 6. THE OPIOID MOVEMENT • In October 2014, the FDA reclassified combination drugs with hydrocodone as Schedule II drugs (HIGH POTENTIAL FOR ABUSE!!!) • Methadone and Oxycodone are also Schedule II drugs • This requires patients to see their doctors to obtain new prescriptions, as opposed to obtaining refills without an office visit • The reclassification limits somewhat the ease of access to opioids
  • 7. AMENDMENTS TO THE WORKERS’ COMPENSATION RULES • The Michigan Workers’ Compensation Agency (WCA) amended the Workers’ Compensation Health Care Services rules and fee schedule, effective December 26, 2014 • The amendments were put in place to address the problem of long- term use of opioids by injured workers and help reduce medical costs for the State’s job providers • Limit potential addiction problems for injured workers, to keep them healthy and get them back to work
  • 8. • Rule 1008. (1) For purposes of these rules, chronic pain is pain unrelated to cancer or is incident to surgery and that persists beyond the period of expected healing after an acute injury episode. It is pain that persists beyond 90 days following the onset of the pain. The payer shall reimburse for opioids used in the treatment of chronic pain resulting from work-related conditions. • (2) This rule is applicable to opioid treatment of chronic pain for the following: (a) Injury dates on or after June 26, 2015. (b) Beginning December 26, 2015, all other injury dates. R 418.101008 Reimbursement for opioid treatment for chronic, non-cancer pain
  • 9. R 418.101008a Required documentation for reimbursement of treatment for chronic, non-cancer pain with opioids. • Rule 1008a. (1) In order to receive reimbursement for opioid treatment beyond 90 days, the physician seeking reimbursement shall submit a written report to the payer not later than 90 days after the initial opioid prescription fill for chronic pain and every 90 days thereafter. The written report shall include all of the following: • (a) A review and analysis of the relevant prior medical history, including any consultations that have been obtained, and a review of data received from an automated prescription drug monitoring program in the treating jurisdiction, such as the Michigan Automated Prescription System (MAPS), for identification of past history of narcotic use and any concurrent prescriptions. • (b) A summary of conservative care rendered to the worker that focused on increased function and return to work. • (c) A statement on why prior or alternative conservative measures were ineffective or contraindicated.
  • 10. • (d) A statement that the attending physician has considered the results obtained from appropriate industry accepted screening tools to detect factors that may significantly increase the risk of abuse or adverse outcomes including a history of alcohol or other substance abuse. • (e) A treatment plan which includes all of the following: (i) Overall treatment goals and functional progress. (ii) Periodic urine drug screens. (iii) A conscientious effort to reduce pain through the use of non-opioid medications, alternative non-pharmaceutical strategies, or both. (iv) Consideration of weaning the injured worker from opioid use. • (f) An opioid treatment agreement that has been signed by the worker and the attending physician. This agreement shall be reviewed, updated, and renewed every 6 months. The opioid treatment agreement shall outline the risks and benefits of opioid use, the conditions under which opioids will be prescribed, and the responsibilities of the prescribing physician and the worker.
  • 11. • (2) The provider may bill the additional services required for compliance with these rules utilizing CPT procedure code 99215 for the initial 90 day report and all subsequent follow-up reports at 90- day intervals. • (3) Providers may bill $25.00 utilizing code MPS01 for accessing MAPS or other automated prescription drug monitoring program in the treating jurisdiction.
  • 12. R 418.101008b Denial of reimbursement for prescribing and dispensing opioid medications used to treat chronic, non-cancer pain. • Rule 1008b. Reimbursement for prescribing and dispensing opioid medications may be denied, pursuant to the act. Denial of reimbursement may occur if the physician reporting and treatment plan requirements as stated in R 418.101008a are not met. Denial of reimbursement shall occur only after a reasonable period of time is provided for the weaning of the injured worker from the opioid medications, and alternative means of pain management have been offered.
  • 13. WHAT DOES ALL OF THIS MEAN? • Limits the ease to which opioids are prescribed • Extra hoops for physicians to jump through in order to get paid • Detailed reports to support the need for opioid treatment • Potential to curb the prescription of opioids in the first place
  • 14. MAPS!
  • 15. IMPACT ON WORK COMP CLAIMS • Opioids are the most common treatment for chronic pain – A 2013 study found that 30% of physician visits for back and/or neck pain resulted in a prescription for opioids – As many as 90% of pain management patients in the U.S. receive opioids for chronic pain – 50% of patients who take opioids daily for 90 days are still taking them daily 5 years later
  • 17. WHAT DO THESE STATS MEAN? • The stats show that family physicians, as opposed to pain management specialists, are prescribing most of the opioids being used today • Once an injured worker goes down the opioid route, the odds of long-term opioid use is significant • Potential problems are on the horizon
  • 18. WHY SHOULD YOU CARE ABOUT OPIOID USE? • Cost of opioids is high – Future medical treatment costs will be significant – Need for periodic drug testing – Potential need for a drug weaning program – Increases the exposure of a given workers’ compensation claim – Could lead to a large MSA amount and be an impediment to settlement
  • 19. HOW TO AVOID OPIOID PROBLEMS • Be sure to direct medical care for the first 28 days after an injury occurs – Could prevent the opioid cycle from starting • If/when opioids are being discussed as part of a treatment plan, consider a second opinion (e.g. IME) • Consider the use of a Nurse Case Manager (NCM) to oversee the treatment plan, once opioids are prescribed – Discuss alternatives to opioid treatment – Monitor the reports from the physicians in support of the continued use of opioids – Once opioids are being used, determine the appropriate plan to wean the injured worker off of the opioids • Contact an attorney to discuss the claim
  • 20. QUESTIONS? Renaldo P. DeFrank, Jr. LeVasseur & DeFrank, P.C. 24725 W. 12 Mile Rd., Ste 230 Southfield, MI 48034 Office: 248-356-8600 Cell: 248-207-6365 www.levasseurlaw.com rdefrank@levasseurlaw.com